论文部分内容阅读
目的探讨米非司酮治疗子宫内膜异位症的临床疗效。方法将128例子宫内膜异位症患者随机分为对照组和治疗组,对照组口服丹那唑,治疗组口服米非司酮。结果对照组总有效率、不良反应发生率、复发率、1年受孕率分别为82.81%、67.19%、62.50%、12.50%,治疗组总有效率、不良反应发生率、复发率、1年受孕率分别为95.31%、34.38%、6.25%、39.39%,两组比较差异均有统计学意义(均P<0.05)。结论米非司酮治疗子宫内膜异位症临床疗效显著、受孕率高、复发率低、不良反应小,值得临床广泛推广。
Objective To investigate the clinical efficacy of mifepristone in the treatment of endometriosis. Methods 128 cases of endometriosis were randomly divided into the control group and the treatment group, the control group oral administration of Danazol, the treatment group oral mifepristone. Results The total effective rate, adverse reaction rate, recurrence rate and 1-year conception rate in the control group were 82.81%, 67.19%, 62.50% and 12.50% respectively. The total effective rate, adverse reaction rate, recurrence rate and 1-year pregnancy rate Rates were 95.31%, 34.38%, 6.25% and 39.39%, respectively, with significant difference between the two groups (all P <0.05). Conclusion The efficacy of mifepristone in the treatment of endometriosis has significant clinical effect, high conception rate, low recurrence rate and small adverse reactions. It is worth widely clinical promotion.